Published in FASEB J on August 06, 2007
Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens (2010) 1.43
Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med (2012) 1.19
NOX1, 2, 4, 5: counting out oxidative stress. Br J Pharmacol (2011) 1.08
Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells. Respir Res (2009) 1.00
Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training. PLoS One (2013) 0.86
The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase. Br J Pharmacol (2010) 0.85
Hypoxia induces downregulation of soluble guanylyl cyclase β1 by miR-34c-5p. J Cell Sci (2012) 0.82
Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes. Br J Pharmacol (2011) 0.79
Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia. Am J Respir Cell Mol Biol (2013) 0.76
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract (2014) 0.76
Aberrant cGMP signaling persists during recovery in mice with oxygen-induced pulmonary hypertension. PLoS One (2017) 0.75
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension (2007) 5.80
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 4.63
Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res (2012) 4.19
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69
Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem (2004) 3.37
Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res (2007) 3.28
Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem (2003) 3.23
Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation (2005) 3.12
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med (2003) 2.90
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med (2004) 2.80
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med (2005) 2.69
Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med (2008) 2.68
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov (2006) 2.64
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med (2003) 2.59
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest (2006) 2.52
Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell (2011) 2.51
NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Invest (2013) 2.48
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol (2006) 2.29
Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation (2002) 2.20
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med (2002) 2.08
Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+,K+-ATPase. Am J Respir Cell Mol Biol (2005) 1.91
Pulmonary vascular disease in the developing world. Circulation (2008) 1.90
Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A (2006) 1.89
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med (2002) 1.72
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol (2002) 1.67
Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome? Am J Respir Crit Care Med (2004) 1.66
Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol (2005) 1.66
NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res (2005) 1.65
Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood (2010) 1.62
NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther (2008) 1.58
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation (2006) 1.55
Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost (2004) 1.53
NADPH oxidases in cardiovascular disease. Free Radic Biol Med (2010) 1.53
Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injury--role of platelet-activating factor receptor. Crit Care Med (2007) 1.52
Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax (2010) 1.52
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med (2014) 1.48
Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol (2007) 1.47
Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thromb Haemost (2006) 1.46
The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci (2012) 1.44
Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J (2005) 1.44
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol (2003) 1.43
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol (2004) 1.42
Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. J Aerosol Med (2006) 1.41
Leukotriene-mediated coronary vasoconstriction and loss of myocardial contractility evoked by low doses of Escherichia coli hemolysin in perfused rat hearts. Crit Care Med (2003) 1.41
Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med (2011) 1.37
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension (2006) 1.34
Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia (2009) 1.34
Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med (2006) 1.33
Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med (2004) 1.31
Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood (2005) 1.31
Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun (2006) 1.30
Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res (2009) 1.29
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.29
Role of Nox4 in murine models of kidney disease. Free Radic Biol Med (2012) 1.28
Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med (2003) 1.28
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation (2007) 1.28
Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J (2008) 1.28
In vivo TRPC functions in the cardiopulmonary vasculature. Cell Calcium (2007) 1.26
Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. Am J Physiol Heart Circ Physiol (2004) 1.26
Essential role of complex II of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol (2003) 1.25
Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. Nat Commun (2012) 1.25
Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus. J Neurosci (2002) 1.24
Good stress, bad stress--the delicate balance in the vasculature. Dtsch Arztebl Int (2009) 1.23
Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension (2010) 1.23